Experiment 69629
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Hypericum perforatum (CLUSIACEAE) |
| Citation | HENDERSON,L: YUE,QY: BERGQUIST,C: GERDEN,B: ARLETT,P:. (2002). ST JOHN'S WORT (HYPERICUM PERFORATUM): DRUG INTERACTIONS AND CLINICAL OUTCOMES.. 54(4) |
| Amount utilized | |
| Compound isolated | |
| Disease | TREAT MIGRAINE WERE IDENTIFIED. THESE INTERACTIONS ARE ASSOCIATED WITH AN INCREASED RISK OF ADVERSE REACTIONS. AS THE VARIABLES QUALITY AND QUANTITY OF CONSTITUENTS IN SJW PREPARATIONS. IN ADDITION, POSSIBLE PHARMACODYNAMIC INTERACTIONS WITH SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS AND SEROTONIN (5-HT(1D)) RECEPTOR-AGONISTS SUCH AS TRIPTANS USED TO MEDICINES. THESE INTERACTIONS ARE PROBABLY DUE TO THE INDUCTION OF CYTOCHROME P450 ISOENZYMES CYP3A4, CYP2C9, CYP1A2 AND THE TRANSPORT PROTEIN P-GLYCOPROTEIN BY CONSTITUENTS IN SJW. THE DEGREE OF INDUCTION IS UNPREDICTABLE DUE TO FACTORS SUCH INTERACTIONS HAVE BEEN IDENTIFIED WITH PRESCRIBED MEDICINES INCLUDING WARFARIN, PHENPROCOUMON, CYCLOSPORIN, HIV PROTEASE INHIBITORS, THEOPHYLLINE, DIGOXIN AND ORAL CONTRACEPTIVES RESULTING IN A DECREASE IN CONCENTRATION OR EFFECT OF THE A SYSTEMIC REVIEW OF ALL THE AVAILABLE EVIDENCE,INCLUDING WORLDWIDE PUBLISHED LITERATURE AND SPONTANEOUS CASE REPORTS PROVIDED BY HEALTHCARE PROFESSIONALS AND REGULATORY AUTHORITIES WITHIN EUROPE WAS PERFORMED.A NUMBER OF CLINICALLY SIGNIFICANT |
| Dose amount | 900.0 MG |
| Number | 2 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | HYDRO-ALCOHOLIC EXT |
| Gender | GIVEN TO BOTH SEXES |